Table 1 Rates of AKI and RRT in hospitalized patients with COVID-19
Study Population | N | ICU (%) | Comorbidities | AKI definition | AKI (%) | RRT (%) | Mortality in patients with AKI (%) | Ref |
|---|---|---|---|---|---|---|---|---|
China | ||||||||
Wuhan | 116 | 0% | HTN: 37%; DM:16%; CKD: 4% | KDIGO | 0% | 4% | NR | |
Wuhan | 99 | 23% | CVD: 40%; DM: 12% | SCr >1.3 mg/dl | 3% | 9%; 39% in ICU | NR | |
Wuhan | 138 | 26% | HTN: 31%; DM: 10%; CKD: 3% | KDIGO | 4%; 8% in ICU | 2%; 6 % in ICU | NR | |
Wuhan | 333 | 17% | HTN: 32%; DM: 23% | KDIGO | 11% (46% stage1; 23% stage 2; 31% stage 3); 43% in ICU | 3% in ICU | 57%; 25% in stage 1; 75% stage 2; 90%; stage 3 | |
Wuhan | 701 | 10% | HTN: 33%: DM:14%; CKD: 2% | KDIGO | 5% (2% stage 1; 1% stage 2; 2% stage 3) | NR | 34% in patients with AKI on admission | |
Wuhan | 41 | 32% | HTN: 15%; CVD: 15%; DM: 20% | KDIGO | 7%; 23% in ICU | 7%; 23% in ICU | NR | |
Wuhan | 274 | - | HTN: 34%; CVD: 8%; DM: 17% | KDIGO | 11% | 1% | NR | |
Wuhan | 191 | 26% | HTN: 30%: DM: 19%; CKD: 1% | KDIGO | 15% | 5% | NR | |
Wuhan | 52 | 100% | CVD: 23%; DM: 17% | KDIGO | 29% | 17% | NR | |
Wuhan | 102 | 18% | HTN: 28%; CVD: 10%; DM: 11%; CKD: 4% | NR | 20% | 6% | NR | |
30 regions | 1,099 | 5% | HTN; 15%; DM: 7%; CKD: 0.7% | KDIGO | 0.5%; 6% in ICU | 0.8%; 12% in ICU | NR | |
Jiangsu | 80 | 0 | CVD: 31%; CKD: 1% | NR | 3% | 1% | NR | |
USA | ||||||||
Washington | 21 | 100% | CKD: 48%; ESRD: 10% | Need for RRT | 19% | NR | NR | |
New York | 5700 | 22% | HTN 56%; CVD:18%; CKD: 5%; ESRD: 4% | KDIGO | 24% | 4% | NR | |
New York | 1000 | 24% | HTN: 60%; CVD: 23%; DM: 37%; CKD: 14% | Defined by clinic notes in EHR | 34%; 78% in ICU | 14%; 35% in ICU | NR | |
New York | 257 | 100% | HTN: 63%; CVD: 19%; DM: 36%; CKD: 14% | NR | NR | 31% | NR | |
New York | 5449 | 26% | HTN: 56%; CVD: 18%; DM: 33% | KDIGO | 37% (47% Stage 1; 22 % Stage 2; 31% Stage 3); 76% in ICU | 23% in ICU | 35% | |
Louisiana | 575 | 30% | HTN: 72%; DM: 48%; CKD: 29% | KDIGO | 28%; 61% in ICU | 15%; 73% in ICU | 50%; 72% in patients on RRT | |
Multicentre | 2215 | 100% | HTN: 60%; CVD: 22%; DM: 39%; CKD: 13%: ESRD: 3% | KDIGO Stage 2 and 3 | 43% | 20% | NR | |
Europe | ||||||||
United Kingdom | 2,743 (April 2020) 10,547 (July 2020) | 100% | CVD: 0.7%: ESRD: 2% | Need for RRT | NR | 20% (April) 27% (July) | 80% (April) 57% (July) | |
